

Investigating understanding, experience and barriers to care for people living with chronic hepatitis B virus infection in Kilifi, Kenya

Louise O Downs^{1,2}, Juliet Odhiambo², Mwanakombo Zaharani², Oscar Chirro², Benson Safari², Nadia Aliyan³, Philippa C Matthews^{4,5,6} and Nancy Kagwanja².

1. Nuffield Department of Medicine, University of Oxford, UK
2. KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya
3. Kilifi County Hospital, Kilifi, Kenya
- 4 The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK
5. Division of Infection and Immunity, University College London, London, UK
6. University College London Hospital, 235 Euston Road, London NW1 2BU, UK

Corresponding author: Louise Downs. Louise.downs@exeter.ox.ac.uk

Keywords: Hepatitis B virus; Patient voice; Lived experience; Barriers to care; Care cascade.

Abstract

Chronic hepatitis B infection (CHB) is a global health disaster with over 1 million people dying annually from this infection worldwide. A large burden of morbidity and mortality is in the WHO-African Region (WHO-AFRO) however here <5% of people are diagnosed and 0.2% on treatment. Community understanding of HBV is often poor and people living with HBV (PLWHB) can experience stigma and discrimination. However there has been little documentation on the impact of an HBV diagnosis on the lives of PLWHB. We explore the experience of PLWHB in Kilifi, Kenya, including their understanding of the disease, how their diagnosis has changed their lives and what barriers they have experienced when accessing care. We show overall understanding of HBV in this group is good, with most participants knowing transmission routes and available treatment. In the general community however, HBV understanding is poor - there is no local name for the infection other than the symptoms it causes such as swollen tummy and yellow eyes. Many participants felt shocked at their initial diagnosis and had mixed reactions from friends and family. Costs of transport and concerns about lost employment were seen as the biggest barrier to care with many people advocating for decentralised clinics. Stigma was also raised with people feeling isolated, rejected and discriminated against. There was also discomfort around the current

integration of HBV and HIV services at KCRH, with concerns over increased stigma, longer waiting times and preferential treatment being given to those living with HIV.

Community education, provision of wider testing and advocacy by well-respected community members were mentioned as key methods to reduce HBV transmission. Decentralisation of clinics may improve access to care; however the patient voice must be considered when planning future interventions to ensure these are acceptable and accessible to the community.

Introduction

Approximately 256 million people worldwide are living with chronic hepatitis B infection (HBV) with the highest burden of infection being in the WHO-African Region (WHO-AFRO) (1). HBV has, however, been neglected in terms of healthcare provision, education, research and policy (2,3). Very few people living with HBV (PLWHB) in WHO-AFRO are diagnosed and knowledge around HBV in communities is often limited (4). Along with this, there has been very little documentation of the impact of HBV on the people living with the infection, particularly in WHO-AFRO populations, although it is widely agreed that the patient voice is urgently needed to improve representation and advocacy, and drive progress towards improved clinical care and global elimination targets (5).

We set out to engage the community living with HBV in Kilifi, Kenya, through focus group discussion (FGDs), as a pilot exercise both to generate evidence to inform care delivery, and as a basis to allow scale up of qualitative data collection in this setting and elsewhere. The aims of these FGDs were: i) to explore understanding of HBV infection both on an individual and community level, ii) to explore how the lives of PLWHB have changed since their diagnosis and iii) to investigate barriers to receiving care and how these could be reduced.

Methods

The STRIKE-HBV study was undertaken at Kilifi County Referral Hospital (KCRH) between March 2023 – May 2024, enrolling 102 PLWHB as previously described (6). KCRH is a referral facility in Coastal Kenya, servicing an area of around 12000 km² and a population of 1.5million people. KCH has 300 inpatient beds and sees 193000 outpatients every year.

Prior to STRIKE-HBV, very few PLWHB were cared for at KCRH, HBV testing was rarely done and not free of charge. All those found to be living with HBV through the STRIKE-HBV study were then referred to the Comprehensive Care Clinic (CCC) for ongoing management. At KCRH, there is no routine mechanism of determining treatment eligibility, therefore all PLWHB receive nucleoside analogue (NA) therapy.

With support from the STRIKE-HBV study team, the CCC initiated 3 monthly peer support group sessions for PLWHB to coincide with medication pickup days. This involved inviting all those living with HBV to the clinic (not just those enrolled in STRIKE-HBV) for information giving and to answer questions. Following one peer support session, the STRIKE-HBV study team invited peer support group attendees who were also enrolled in STRIKE-HBV to participate in two FGDs as part of study monitoring and feedback.

As per the Engagement Monitoring and Evaluation protocol (KEMRI/SERU/CGMRC-C/075/3416 VER. 1.8 25/05/2020), a written consent form was signed by one person in the group on behalf of the whole group, after verbal consent was sought from all focus group participants. This included consent for audio recording of the FGDs. Participants were given a number from 1-6 or 1-7 within their group to anonymously identify respondents.

FGDs were undertaken primarily in Kiswahili by a member of the STRIKE-HBV study team and facilitated by a member of the Community Liaison Group (CLG) from KEMRI-Wellcome Trust Research Programme (KWTRP). FGDs took around 1.5 hours, were audio recorded using a dictation device from KWTRP, and those participating were given refreshments and lost earnings compensation of around USD \$5, as is standard for community engagement activities at KWTRP. Questions used as a guide in the FGDs are shown in appendix 1. Following FGDs, data were transcribed and translated into English and analysed in Nvivo version 15.

Results

Focus groups consisted of six men and seven women with a median age of 37 years (range 24 – 61). Five participants had been newly diagnosed with HBV in the STRIKE-HBV study,

eight already knew their diagnosis prior to study enrolment. Two participants who were newly diagnosed had family members already known to be living with HBV.

i) Knowledge and understanding of HBV

Most people knew that HBV is a virus causing liver disease and is transmitted sexually or by mixing blood. Many people thought sexual transmission was the primary route, whilst others reported this to be mother to child transmission or sharing toothbrushes and razors. Several participants mentioned their concern about being involved in road traffic accidents and transmitting HBV due to bleeding. All participants knew about the medication for HBV, however there was still some confusion around what happens after taking treatment for 6 months - some people thought they would be cured, others knew this wasn't the case:

“Addition, liver disease, you can, if you use the medicine properly for six months and if you are tested, it may be that the virus is gone”, (participant 5, FGD 1).

When discussing a local language description of HBV, several participants said it was an unknown disease:

“But this hepatitis B virus is unknown, let's say it has no name. People don't know, they only know AIDS”, (participant, FGD 2).

Some people reported it was only described as liver disease:

“It's just liver. If his legs and stomach swell, his eyes are yellow, at the last minute they will say it's liver”, (participant, FGD 2).

Others reported it was called either 'pregnancy' or 'cancer'. Several people did mention that they had heard of it in the past as it was causing illness in their village, and it was felt to be a death sentence:

“I knew it [HBV] was killing people in the village. You don't know if he is starting [to get unwell] but you will only know that something has reached. That is, they don't

get medicine, that is, there is no nursing, it is only when he is taken to the hospital, when he begins to be treated, then death has already arrived” (participant 6, FGD 1).

Several respondents mentioned that due to the lack of understanding of HBV, people with HBV were thought to be bewitched and they would go to witchdoctors or to church to pray to be cured from HBV.

ii) Confusion with HIV

Many people discussed the confusion between HBV and HIV particularly given care is received in the same clinic and the medication is the same, they found it hard to explain the difference. Many friends and family members had accused participants of lying about having HIV infection, and many people felt they had to ‘prove’ they didn’t have HIV by going with family or partners to have a test:

“...and you feel that I’m lying to you that I have AIDS. You have gone and you have been tested, I had to come with him and we were both tested and we were fine”, (participant 6, FGD 1),

“...one day my wife came and explained to me, "I heard some people say that you have AIDS." I told her, "No, I don't have AIDS and even if you want to know, let's come, let's all come and be tested" (participant 5, FGD 2).

iii) Symptoms of HBV

We discussed symptoms of HBV with the groups. Several people reported non-specific symptoms that had improved with treatment such as fatigue, stomach pains, swollen stomach, nausea and vomiting, itching, heartburn and trouble defecating. Symptom improvement with treatment encouraged them to continue:

“I was given about five days [of medication]. I came back, I came and was given for two weeks, I came back. But since then, I see changes myself even in my body. I don’t get hurt a lot and I don't get a lot of fatigue”. (participant 7, FGD 1).

"I was diagnosed with this disease, and I just saw that I was already dying. But when I got this treatment, now I am fine because even I myself was sleeping and I could feel my stomach like water going this way, when I turned over, I could feel like water coming back this way and I said, "My stomach has started to swell too." But this time when I started this treatment, that issue stopped and the anxiety of saying that I was dying because I had not received training, this time I have received training. Now I know that if I use these drugs properly, I can live normally." (participant 5, FGD 1).

iv) How lives have changed since HBV diagnosis

We initially discussed reactions to diagnosis, both individually and those of friends and family. Many were shocked at their diagnosis and felt anxious as they didn't understand what HBV was. Counselling improved this and helped alleviate anxiety, and peer support sessions were found to be motivating. Several people mentioned that once they got used to their diagnosis, they realised they could continue to take the medication and live just like anyone else.

Many people had been tested as a condition for travelling abroad for work, and their diagnosis had not been properly explained to them which caused a lot of distress:

"He told me, "...He refused to tell me because he said [the problem was] either liver or kidney. I told him, "Now there is no disease that is good and there is no disease which is bad, you can just explain it to me." He said, "Just go to the doctor and get tested or go and get an x-ray and he will explain more, but I won't explain it to you.""(participant 3, FGD 2).

They felt lost and abandoned, unable to pursue their plans, whilst peers and colleagues went off on their travels. Reactions of friends and family varied. Some were very supportive, went to get tested themselves and encouraged participants to continue medication. Sometimes after initial lack of understanding, relatives came to the CCC to understand more about the disease.

Almost all participants commented that their lives had changed since HBV diagnosis, sometimes in beneficial ways, some less so. One participant had considerably cut his alcohol consumption due to concerns about his liver:

“Even that time I came to be tested, I came already drunk...I have been told “The liver's job is this and this and this and when you eat, the food is processed like this and this and this in the stomach”... I saw that there is a very important knowledge.... I stopped drinking alcohol; I continue to take medicine. So I see there is a big change. That is, since I have been drunk all the time and this time, I can be sober, I'm grateful”, (participant 1, FGD 1).

Many participants mentioned they had less freedom in the evenings now as they needed to ensure they were home from work at a particular time and sometimes couldn't go out and meet friends due to taking their medication:

“But since I use these drugs, I always tell my friends that I can't walk at night. Because when it reaches eight o'clock, I have to take medicine” (participant 7, FGD 1).

Most people set an alarm as a reminder, with a few associating it with their favourite TV show time, or the evening call to prayer.

v) *Barriers to HBV care and how these can be reduced*

Economic factors seemed to be the biggest barriers to receiving care. Firstly the cost of transport to attend the hospital-based clinic was frequently mentioned as a challenge. Many people felt medication should be available at the local dispensary due to cheaper travel costs and less time spent travelling and waiting to be seen:

“Because the rest of us are far away [from the hospital], but if we find our local dispensaries nearby, these local medicines, the way we are known, they are placed there. It will be easy even for us because we won't have to pay fare”, (participant, FGD 1).

Several FGD participants mentioned the need to plan ahead to make sure they had fare to attend clinic. Along with fare, the timing of clinic appointments had little flexibility, and often the patients experienced long waiting times. This was difficult with employment, struggling to get days off work and causing lost earnings:

“So the challenge always arises because maybe your boss refuses to agree with you, maybe if it [the clinic return date] can be balanced until you get the chance to come take medicine or a meeting like this. You may find that your boss telling you, “Now it may be that you will not get paid today, or this day for you, we will remove it from your rest days, we will cut it there””, participant 5, FGD 2).

Several participants had experienced stigma or discrimination, often feeling people were talking about them and others were distancing themselves for fear of infection:

“And if the food itself I can't eat with them at the same table, it is as if I will infect them, I should have my own bowl and sit aside”, (participant, FGD 1).

As noted earlier, HIV and HBV services are currently integrated in KCRH and all patients are seen together in the same clinic. There was a lot of discussion about this, with many participants feeling they should have a separate clinic from those living with HIV, partly due to stigma when seen entering the HIV clinic, but also due to long wait times when being seen together. Some people felt those living with HIV were prioritised, although there was also agreement that separating those with HBV and HIV would only increase stigma, and they should all be together because they had more in common than differences:

“I see they should just be together because we cannot separate them [HIV patients]. We all say we are birds of the same colour, we are going in the same direction. It means that if we separate them, it is like we are bringing that stigma and we don't want it to be like that”, (participant, FGD 2).

vi) *Reducing transmission*

When asking FGD participants how to reduce HBV transmission, some people mentioned practical ways to reduce contact with the virus. Safe sexual practices were mentioned several times, and one participant mentioned wearing gloves before helping anyone who was injured for example in a road traffic accident. Reducing the sharing of instruments that spread HBV was felt to be important, particularly needles, razors and toothbrushes, and a few participants mentioned vaccination, but did not distinguish groups they felt could benefit from vaccination, or how vaccination should be offered.

Community awareness was felt to be paramount in stopping the spread of HBV. Ensuring the community understands that HBV causes liver disease and untreated it can be dangerous, but also to promote that there is treatment available and with treatment, HBV can be managed and may not be as bad as people think. Participants suggested that improved community knowledge would help those living with HBV feel less isolated, and this knowledge could be spread by religious leaders, CHVs, online church webinars and Ministry of Health officials promoting testing through radio and TV campaigns:

"So you find when people already know that [HBV can be dangerous], if the pastors also intervene, after explaining, now you get a large group that will now say, "Uh, let me look at myself." And there I think we will find a large number of people who will volunteer [for HBV testing] because this is volunteering. You can't say you go to someone house and grab his shirt and bring him here, no, it's up to him to decide and say, "At my own free will, let me check."", (participant 6, FGD 2).

Increased testing was also mentioned by several participants, ensuring the community knows this is available, where to be tested and ideally testing being offered for free. Many discussed that HBV testing should be part of the routine screening that everyone has when they go to a hospital, like HIV. There was also discussion of the benefits of antenatal testing for HBV, and how this should be routine:

"...perhaps if the pregnant mother it is her first time, she must come with her husband so that they can be tested for AIDS, and the likes. Now I was thinking that maybe it would also be good if this hepatitis B was placed in that category, when

they come to be tested, if he has come to the clinic, being tested for the HIV virus, they should also test the Hepatitis B virus...”, (participant 6, FGD 2)

Reducing stigma around an HBV diagnosis was felt to be key in reducing transmission. If those living with HBV felt able to reveal and discuss their diagnosis, they could also be the ones to spread awareness and educate their communities:

“I think it would be better for those of us who have the disease to not be ashamed. I explain that I... was diagnosed with that disease and that I use those drugs, I tell the people there to go to the hospital, not to wait until the organization takes time to reach the grassroots, it will be too late”, (participant 2, FGD 2).

Discussion

We held FGDs with PLWHB in Kilifi, Kenya, exploring the impact of the HBV diagnosis on their lives, barriers to care and views about how these could be reduced. This article adds to the limited literature exploring the lives of PLWHB in WHO-AFRO countries.

We found cost to be a significant barrier to HBV care, which has also been shown elsewhere (7–9), although in our study, travel costs to the hospital clinic were seen as most prohibitive, whereas in studies from Burkina Faso and Ghana, costs of tests, monitoring and medications were mentioned more commonly (8,10). This may be because in our study testing was free of charge, and nucleoside analogue therapy was also provided free at the point of care in Kilifi County Hospital which is not the case in many other countries. Many studies both from within WHO-AFRO and further afield raised concerns around lost employment. This ranged from lost work days to attend clinic appointments to being prevented from travelling abroad for work and discrimination in the work place (11–13) and is very similar to what we found in our study. Lack of childcare was mentioned as a significant barrier to care in some studies outside of WHO-AFRO (12). This was not mentioned at all in our study or others from Ghana or Burkina Faso possibly due to the different family structures in countries in WHO-AFRO compared to those in the Global North, with less reliance on parents being the sole care givers.

The concerns raised by our participants around the integration of HBV and HIV care particularly related to increased stigma has been discussed previously (14). The utilisation of existing HIV services is one of the key components hypothesised to enable decentralisation of HBV care given HIV facilities are spread widely around WHO-AFRO countries in smaller clinics and dispensaries. We suggest that caution is needed, and extensive community education and sensitisation should be done before this is implemented. We also found that there is often confusion between HIV and HBV, which was also the case in Burkina Faso where HBV was closely associated with HIV when explained to patients (8). Although this was seen as a negative association, the good understanding of HIV transmission routes did help explain HBV transmission. In Burkina Faso, those diagnosed with HBV outside of a hospital setting were often given poor information around HBV, similar to several of our participants who were diagnosed pre-travel.

An interesting finding in our study was that many people felt they were restricted in the evenings due to taking medication, having to be home from work at a particular time or being unable to meet friends. Exploration is needed as to why this is the case and suggests a need for education to promote understanding that HBV medication can take be taken at any time of day as long as this is consistent.

Several studies have evaluated different mechanisms to try and improve HBV care, however very few have included the patient voice when planning interventions (15,16). When exploring how PLWHB felt transmission could be reduced, community education was seen as paramount in this effort, along with making testing more accessible. Several suggestions from participants here are already included in national Kenyan guidelines on the management of HBV such as antenatal HBV testing and provision of HBV vaccination to close family contacts (17), however these are not routinely incorporated into care.

Caveats and limitations

We only included PLWHB in this study who were already linked to care and had participated in a previous research study. This group are likely to have better knowledge than those not enrolled in such a study and be more engaged in care. This study is also from a limited geographical area and included a small number of PLHWHB. To expand the study, we would

undertake similar discussions with PLWHB who have been lost to follow up to see whether any other care barriers can be elicited, along with healthcare workers and community groups not living with HBV. We would expand the study to include PLWHB from other health providers both in Kilifi and further afield.

Conclusions

Community education and decentralisation of care for PLWHB should be prioritised to reduce stigma, enable easier access to care, reduce travel times and costs in order to reduce health inequities and support wider roll-out of treatment. Including patient voice in understanding barriers to care is critical to ensure interventions are appropriate.

Funding

This project is funded by the Wellcome Trust (grant 225485/Z/22/Z) and the John Fell Fund, University of Oxford (ref: 0012112).

Conflicts of Interest

PCM has previously received funding from GSK for a PhD student in her group. This has had no influence over the planning or undertaking of the study, the writing of the manuscript or decision to publish.

Resources

Educational resources developed for the STRIKE-HBV study available from:

<https://doi.org/10.6084/m9.figshare.c.7114813.v2>

References

1. Global hepatitis report 2024: action for access in low- and middle-income countries [Internet]. World Health Organization; 2024 [cited 2024 Jun 4]. Available from: <https://www.who.int/publications/i/item/9789240091672>
2. O'Hara GA, McNaughton AL, Maponga T, Jooste P, Ocama P, Chilengi R, et al. Hepatitis B virus infection as a neglected tropical disease. PLoS Negl Trop Dis [Internet]. 2017 Oct 5;11(10). Available from: <http://dx.doi.org/10.1371/JOURNAL.PNTD.0005842>

3. Delphin M, Mohammed KS, Downs LO, Lumley SF, Waddilove E, Okanda D, et al. Under-representation of the WHO African region in clinical trials of interventions against hepatitis B virus infection. *Lancet Gastroenterol Hepatol*. 2024 Feb 15;9(4):383–92.
4. Mugisha J, Mokaya J, Bukenya D, Ssembajja F, Mayambala D, Newton R, et al. A Study of Knowledge, Experience, and Beliefs About Hepatitis B Virus (HBV) Infection in South Western Uganda. *Front Public Health*. 2019 Oct 25;7:304.
5. Matthews PC, Jack K, Wang S, Abbott J, Bryce K, Cheng B, et al. A call for advocacy and patient voice to eliminate hepatitis B virus infection. *Lancet Gastroenterol Hepatol*. 2022 Apr;7(4):282–5.
6. Downs LO, Chirro O, Zaharani M, Safari B, Okanda D, Githinji G, et al. STRIKE-HBV: establishing an HBV screening programme in Kilifi, Kenya-challenges, successes and lessons learnt. *Sex Transm Infect* [Internet]. 2024 May 24; Available from: <http://dx.doi.org/10.1136/sextrans-2024-056163>
7. Lu J, Xu A, Wang J, Zhang L, Song L, Li R, et al. Direct economic burden of hepatitis B virus related diseases: evidence from Shandong, China. *BMC Health Serv Res*. 2013 Jan 31;13(1):37.
8. Giles-Vernick T, Hejoaka F, Sanou A, Shimakawa Y, Bamba I, Traoré A. Barriers to Linkage to Care for Hepatitis B Virus Infection: A Qualitative Analysis in Burkina Faso, West Africa. *Am J Trop Med Hyg*. 2016 Dec 7;95(6):1368–75.
9. Adjei CA, Naab F, Donkor ES. Beyond the diagnosis: a qualitative exploration of the experiences of persons with hepatitis B in the Accra Metropolis, Ghana. *BMJ Open*. 2017 Nov 3;7(11):e017665.
10. Adjei CA, Stutterheim SE, Naab F, Ruitter RAC. Chronic Hepatitis B stigma in Ghana: a qualitative study with patients and providers. *BMJ Open*. 2019 Jun 27;9(6):e025503.
11. Freeland C, Farrell S, Kumar P, Kamischke M, Jackson M, Bodor S, et al. Common concerns, barriers to care, and the lived experience of individuals with hepatitis B: a qualitative study. *BMC Public Health*. 2021 May 28;21(1):1004.
12. Tang LY, Pene F, Cherfas L, Schwartz J, Baquero MC. Facilitators and barriers to accessing hepatitis B care in the postpartum period among foreign-born New Yorkers: a qualitative analysis of case notes. *BMC Public Health*. 2024 Jan 8;24(1):116.
13. Taheri Ezbarami Z, Hassani P, Zagheri Tafreshi M, Alavi Majd H. A qualitative study on individual experiences of chronic hepatitis B patients. *Nurs Open*. 2017 Oct;4(4):310–8.
14. Mutyoba JN, Wandera C, Ejalu D, Seremba E, Beyagira R, Amandua J, et al. Feasibility and acceptability of integrating hepatitis B care into routine HIV services: a qualitative study among health care providers and patients in West Nile region, Uganda. *BMC Health Serv Res*. 2023 Jan 20;23(1):59.

15. Wong RJ, Khalili M. A patient-centered hepatitis B virus (HBV) educational intervention improves HBV care among underserved safety-net populations. *J Clin Gastroenterol*. 2020 Aug;54(7):642–7.
16. Jonas MC, Sheu Y-S, Wright K, Peyton L, Bishop RC, Basra S, et al. A care coordination program to support patients with hepatitis B virus at Kaiser Permanente Mid-Atlantic States. *BMC Health Serv Res*. 2024 Apr 18;24(1):482.
17. Kenyan Ministry for Health. Kenyan Ministry for Health Guidelines Immunisation.pdf. 2023 Apr.

Appendix 1: Questions used in focus group discussions with people living with hepatitis B virus infection.

1) UNDERSTANDING

- a) What do you understand about HBV now?
 - i) Transmission routes?
 - ii) Treatment
 - iii) Do you have any thoughts on how transmission could be stopped? E.g. vaccines, testing being more accessible
- b) Has your understanding of HBV changed since your diagnosis?
- c) Has your lifestyle changed since your diagnosis and how?
- d) Do you feel well informed about your diagnosis?

2) DESCRIBING HBV

- a) What word do you use for hepatitis B in your local community?
- b) Are there any other words by which it is known?

3) REACTIONS TO DIAGNOSIS

- a) Who have you told about your diagnosis? How have they reacted?
- b) Have you felt isolated/stigmatised/discriminated against? E.g. employment lost etc..
- c) Do you think the community needs to understand more about HBV?
- d) If yes, how could this be done?

4) RECEIVING CARE

- a) Is it easy for you to come to the clinic to get your medication for HBV?
- b) If not, what are the barriers for you? E.g. lost work days, expensive
- c) How do you find taking the medication?
- d) Are there any special things you do to remember to take it every day?
- e) What could be done to improve your treatment? Such as longer supplies of medication, clinics in rural areas, separate hepatitis clinics, shorter waiting times.

5) HEALTHCARE WORKERS PERCEPTIONS

- a) How do you feel healthcare workers perceive you when they know you have HBV?
- b) Do you feel treated differently?
- c) Do you feel healthcare workers are well informed about HBV?

